# Multiplexed device for rapid coagulopathy testing

> **NIH NIH R21** · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $462,000

## Abstract

Abstract
COVID-19 has emerged as a global health challenge, with more than 37 million cases reported and 1,079,029
deaths (as of October 13, 2020 according to the WHO website). Although the precise etiology of coagulopathies
in COVID-19 is not clear, damage to lung tissue, increased cytokine levels and alteration of blood chemistry due
to inflammation and sepsis all likely contribute. The resulting inappropriate hemostasis (the process of making
blood clots to stop bleeding) is a major challenge in the care of these patients. Importantly, the coagulation
profile of a COVID-19 patient – and consequently the appropriate medical treatment – might change from hour
to hour. Because asymptomatic patients can develop life-threatening coagulopathy-related thrombotic events,
robust, frequent and inexpensive tests for blood coagulation aberrations would help identify at-risk patients.
Current methods for clinical assessment of coagulation status are cumbersome, expensive and limited in scope,
and clinicians are frustrated by the lack of robust tools to address coagulopathy in COVID-19. Leveraging our
expertise in blood coagulopathy, COVID-19 management and microfluidics technology, we propose to develop
and test technology for improving diagnosis of blood coagulation status in COVID-19-positive patients. The
technology is simple, but multiplexed, replacing multiple blood tests currently used in the clinic. Because the
blood sample is always contained within the device, risk of exposure to infected blood is minimized. It uses
biomimetic principles to challenge blood to flow through vascular-like channels that are pre-treated with specific
coagulation factors. We will optimize the design of the device and validate its performance against existing assay
methods. When complete, this project will provide new technology for rapid, repeated point of care testing of
blood coagulopathy in COVID-19 and other diverse clinical applications.

## Key facts

- **NIH application ID:** 10285382
- **Project number:** 1R21EB031982-01
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Charles Corey Hardin
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $462,000
- **Award type:** 1
- **Project period:** 2021-09-15 → 2023-09-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10285382

## Citation

> US National Institutes of Health, RePORTER application 10285382, Multiplexed device for rapid coagulopathy testing (1R21EB031982-01). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10285382. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*